Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
68.14
+0.77 (1.14%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Halozyme Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 8,042 | 7,914 | 6,083 | 4,882 | 7,694 | 5,659 | Upgrade
|
| Market Cap Growth | 13.68% | 30.11% | 24.59% | -36.54% | 35.96% | -1.84% | Upgrade
|
| Enterprise Value | 10,076 | 8,751 | 6,951 | 5,929 | 8,940 | 5,722 | Upgrade
|
| Last Close Price | 68.14 | 67.30 | 47.81 | 36.96 | 56.90 | 40.21 | Upgrade
|
| PE Ratio | 26.62 | 24.98 | 13.70 | 17.34 | 38.06 | 14.05 | Upgrade
|
| Forward PE | 8.50 | 8.85 | 10.38 | 9.77 | 21.92 | 17.89 | Upgrade
|
| PS Ratio | 5.76 | 5.67 | 5.99 | 5.89 | 11.66 | 12.76 | Upgrade
|
| PB Ratio | 164.41 | 162.13 | 16.72 | 58.26 | 45.31 | 28.73 | Upgrade
|
| P/TBV Ratio | - | - | - | - | - | 28.73 | Upgrade
|
| P/FCF Ratio | 12.48 | 12.28 | 12.99 | 13.08 | 32.70 | 18.99 | Upgrade
|
| P/OCF Ratio | 12.34 | 12.15 | 12.70 | 12.57 | 32.04 | 18.90 | Upgrade
|
| PEG Ratio | - | 0.41 | 0.41 | 0.41 | 0.41 | 0.46 | Upgrade
|
| EV/Sales Ratio | 7.21 | 6.27 | 6.85 | 7.15 | 13.54 | 12.91 | Upgrade
|
| EV/EBITDA Ratio | 11.22 | 9.75 | 11.09 | 14.22 | 26.60 | 20.63 | Upgrade
|
| EV/EBIT Ratio | 12.34 | 10.72 | 12.61 | 17.56 | 30.89 | 20.74 | Upgrade
|
| EV/FCF Ratio | 15.63 | 13.58 | 14.84 | 15.88 | 37.99 | 19.20 | Upgrade
|
| Debt / Equity Ratio | 44.60 | 44.60 | 4.14 | 18.27 | 9.07 | 4.47 | Upgrade
|
| Debt / EBITDA Ratio | 2.40 | 2.40 | 2.38 | 3.59 | 4.54 | 3.15 | Upgrade
|
| Debt / FCF Ratio | 3.38 | 3.38 | 3.22 | 4.10 | 6.55 | 2.95 | Upgrade
|
| Net Debt / Equity Ratio | 41.68 | 41.68 | 2.50 | 14.26 | 6.94 | 0.70 | Upgrade
|
| Net Debt / EBITDA Ratio | 2.27 | 2.27 | 1.45 | 2.87 | 3.51 | 0.50 | Upgrade
|
| Net Debt / FCF Ratio | 3.16 | 3.16 | 1.94 | 3.20 | 5.01 | 0.47 | Upgrade
|
| Asset Turnover | 0.61 | 0.61 | 0.54 | 0.46 | 0.45 | 0.53 | Upgrade
|
| Inventory Turnover | 1.95 | 1.95 | 1.77 | 2.36 | 2.67 | 2.04 | Upgrade
|
| Quick Ratio | 3.30 | 3.30 | 6.50 | 5.07 | 4.54 | 7.10 | Upgrade
|
| Current Ratio | 4.66 | 4.66 | 7.80 | 6.64 | 5.65 | 7.91 | Upgrade
|
| Return on Equity (ROE) | 153.59% | 153.59% | 198.42% | 222.07% | 110.23% | 231.44% | Upgrade
|
| Return on Assets (ROA) | 22.24% | 22.24% | 18.16% | 11.80% | 12.28% | 20.47% | Upgrade
|
| Return on Invested Capital (ROIC) | 32.36% | 33.01% | 34.44% | 20.77% | 27.92% | 105.98% | Upgrade
|
| Return on Capital Employed (ROCE) | 34.80% | 34.80% | 28.70% | 20.80% | 16.90% | 27.90% | Upgrade
|
| Earnings Yield | 3.94% | 4.00% | 7.30% | 5.77% | 2.63% | 7.12% | Upgrade
|
| FCF Yield | 8.02% | 8.14% | 7.70% | 7.65% | 3.06% | 5.27% | Upgrade
|
| Buyback Yield / Dilution | 4.26% | 4.26% | 3.56% | 4.56% | 4.21% | -3.77% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.